JPRN-UMIN000020027已完成未知
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particles - Effect of canagliflozin for the size of lipid particles
Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy0 个研究点目标入组 30 人开始时间: 2016年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity of canagliflozin 2) Severe ketosis, diabetic coma or precoma 3) Severe infection, pre or post surgery, or severe trauma 4) Patients taking fibrate-based medicines or pioglitazone 5) Patients taking diuretic medicines 6) eGFR < 45 mL/min/1.73 m2 or artificial dialysis 7) Considered as inadequate by the investigator
研究者
相似试验
已完成
不适用
Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgerypatients with diabetes mellitus underwent cardiac surgeryJPRN-UMIN000021239Sekino Hospital30
已完成
不适用
Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DMDiabetes mellitus type 2JPRN-UMIN000024922Sekino Hospital30
尚未招募
4 期
The role of SGLT-2 inhibitors (Empagliflozin) in treating steroid induced hyperglycaemia in the management of glucocorticoid induced hypoerglycaemia in adults with and without diabetes.ACTRN12620000745943Endocrinology Department, Gosford Hospital30
撤回
4 期
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 InsulinDiabetes, ObesityNCT02597309Joslin Diabetes Center
尚未招募
不适用
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54